Lifecore Injectables CDMO was selected to support Indomo, a clinical-stage company developing innovative device-enabled therapeutics, with a range of services for ongoing development of its corticosteroid drug candidate, DT-001. 

Indomo is developing DT-001 to be combined with its investigational intradermal self-injection device, the ClearPen, as a treatment for inflammatory acne lesions. Lifecore recently completed formulation and process optimization for Indomo and will now be responsible for producing and supplying engineering and clinical batches of DT-001 for planned studies designed to prepare the product for anticipated Phase 2 clinical trials in 2026.

“We are thrilled to continue to grow our relationship with Indomo and support a customer that possesses such high-quality leadership and ambitious plans for innovation. This work with Indomo highlights the success of our continued efforts to expand beyond our traditional focus in ophthalmic therapies, while also enhancing our leadership in rapidly growing autoinjector technologies,” said Paul Josephs, president and chief executive officer of Lifecore. 

Indomo’s investigational ClearPen system pairs a proprietary self-injection device and microneedle with a modernized formulation of triamcinolone acetonide. Indomo aims to improve access to treatment by pursuing an at-home approach to patient care. 

“As we progress toward Phase 2 studies, it was critical for Indomo to partner with a CDMO that combines technical excellence with a forward-looking approach to innovation. Lifecore’s expanding leadership in injectable therapeutics and their commitment to speed and high-quality execution position them as a key partner in advancing our therapeutic pipeline. We are excited to deepen this collaboration as we move into the next phase of development,” said Rick Bente, chief executive officer of Indomo.